vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and TANDY LEATHER FACTORY INC (TLF). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $22.3M, roughly 1.7× TANDY LEATHER FACTORY INC). TANDY LEATHER FACTORY INC runs the higher net margin — -4.2% vs -161.8%, a 157.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 8.7%). TANDY LEATHER FACTORY INC produced more free cash flow last quarter ($4.0M vs $-71.3M).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Tandy Leather Factory, Inc. is an American specialty retailer and wholesale distributor of leather and leatherwork related products. It operates more than 100 stores worldwide. Originally part of the Tandy Corporation, Tandy Leather has gone through a series of acquisitions and mergers, eventually being sold to The Leather Factory in 2000. The Tandy Leather flagship store next to their corporate headquarters in Fort Worth, Texas also houses the Al and Ann Stohlman Leathercraft Museum.

IBRX vs TLF — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.7× larger
IBRX
$38.3M
$22.3M
TLF
Growing faster (revenue YoY)
IBRX
IBRX
+398.3% gap
IBRX
407.0%
8.7%
TLF
Higher net margin
TLF
TLF
157.6% more per $
TLF
-4.2%
-161.8%
IBRX
More free cash flow
TLF
TLF
$75.3M more FCF
TLF
$4.0M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
TLF
TLF
Revenue
$38.3M
$22.3M
Net Profit
$-61.9M
$-930.0K
Gross Margin
99.0%
54.3%
Operating Margin
-169.0%
-2.8%
Net Margin
-161.8%
-4.2%
Revenue YoY
407.0%
8.7%
Net Profit YoY
-4.7%
-379.3%
EPS (diluted)
$-0.06
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
TLF
TLF
Q4 25
$38.3M
$22.3M
Q3 25
$32.1M
$17.3M
Q2 25
$26.4M
$17.8M
Q1 25
$16.5M
$19.0M
Q4 24
$7.6M
$20.5M
Q3 24
$6.1M
$17.4M
Q2 24
$17.3M
Q1 24
$19.3M
Net Profit
IBRX
IBRX
TLF
TLF
Q4 25
$-61.9M
$-930.0K
Q3 25
$-67.3M
$-1.4M
Q2 25
$-92.6M
$-199.0K
Q1 25
$-129.6M
$11.6M
Q4 24
$-59.2M
$333.0K
Q3 24
$-85.7M
$-132.0K
Q2 24
$101.0K
Q1 24
$525.0K
Gross Margin
IBRX
IBRX
TLF
TLF
Q4 25
99.0%
54.3%
Q3 25
99.4%
58.9%
Q2 25
99.5%
59.5%
Q1 25
99.6%
56.3%
Q4 24
53.0%
Q3 24
57.8%
Q2 24
58.0%
Q1 24
56.7%
Operating Margin
IBRX
IBRX
TLF
TLF
Q4 25
-169.0%
-2.8%
Q3 25
-173.5%
-3.9%
Q2 25
-269.8%
0.4%
Q1 25
-390.1%
1.4%
Q4 24
-919.0%
0.9%
Q3 24
-1314.3%
-1.5%
Q2 24
0.4%
Q1 24
3.4%
Net Margin
IBRX
IBRX
TLF
TLF
Q4 25
-161.8%
-4.2%
Q3 25
-209.8%
-7.8%
Q2 25
-350.3%
-1.1%
Q1 25
-784.9%
60.8%
Q4 24
-783.4%
1.6%
Q3 24
-1404.0%
-0.8%
Q2 24
0.6%
Q1 24
2.7%
EPS (diluted)
IBRX
IBRX
TLF
TLF
Q4 25
$-0.06
$-0.18
Q3 25
$-0.07
$-0.17
Q2 25
$-0.10
$-0.02
Q1 25
$-0.15
$1.47
Q4 24
$-0.08
$0.04
Q3 24
$-0.14
$-0.02
Q2 24
$0.01
Q1 24
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
TLF
TLF
Cash + ST InvestmentsLiquidity on hand
$242.8M
$16.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
$52.6M
Total Assets
$501.9M
$86.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
TLF
TLF
Q4 25
$242.8M
$16.1M
Q3 25
$257.8M
$12.0M
Q2 25
$153.7M
$16.4M
Q1 25
$61.6M
$23.6M
Q4 24
$149.8M
$13.3M
Q3 24
$130.4M
$10.1M
Q2 24
$11.5M
Q1 24
$12.3M
Stockholders' Equity
IBRX
IBRX
TLF
TLF
Q4 25
$-500.5M
$52.6M
Q3 25
$-524.3M
$53.4M
Q2 25
$-570.7M
$56.1M
Q1 25
$-591.4M
$55.8M
Q4 24
$-489.1M
$57.2M
Q3 24
$-745.1M
$57.6M
Q2 24
$57.5M
Q1 24
$57.2M
Total Assets
IBRX
IBRX
TLF
TLF
Q4 25
$501.9M
$86.6M
Q3 25
$519.0M
$84.5M
Q2 25
$402.1M
$76.5M
Q1 25
$303.8M
$77.9M
Q4 24
$382.9M
$74.9M
Q3 24
$364.6M
$73.0M
Q2 24
$72.8M
Q1 24
$72.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
TLF
TLF
Operating Cash FlowLast quarter
$-70.4M
$5.0M
Free Cash FlowOCF − Capex
$-71.3M
$4.0M
FCF MarginFCF / Revenue
-186.2%
18.1%
Capex IntensityCapex / Revenue
2.4%
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M
$-8.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
TLF
TLF
Q4 25
$-70.4M
$5.0M
Q3 25
$-68.9M
$-1.0M
Q2 25
$-79.7M
$-4.0M
Q1 25
$-85.9M
$-536.0K
Q4 24
$-85.1M
$4.5M
Q3 24
$-98.8M
$-535.0K
Q2 24
$-514.0K
Q1 24
$1.1M
Free Cash Flow
IBRX
IBRX
TLF
TLF
Q4 25
$-71.3M
$4.0M
Q3 25
$-69.6M
$-3.0M
Q2 25
$-80.8M
$-7.3M
Q1 25
$-87.0M
$-1.9M
Q4 24
$-87.3M
$3.8M
Q3 24
$-101.6M
$-1.4M
Q2 24
$-715.0K
Q1 24
$-141.0K
FCF Margin
IBRX
IBRX
TLF
TLF
Q4 25
-186.2%
18.1%
Q3 25
-217.2%
-17.2%
Q2 25
-305.9%
-41.0%
Q1 25
-526.9%
-9.8%
Q4 24
-1155.4%
18.8%
Q3 24
-1663.2%
-8.2%
Q2 24
-4.1%
Q1 24
-0.7%
Capex Intensity
IBRX
IBRX
TLF
TLF
Q4 25
2.4%
4.3%
Q3 25
2.3%
11.2%
Q2 25
4.1%
18.7%
Q1 25
6.8%
7.0%
Q4 24
28.0%
3.3%
Q3 24
45.7%
5.1%
Q2 24
1.2%
Q1 24
6.4%
Cash Conversion
IBRX
IBRX
TLF
TLF
Q4 25
Q3 25
Q2 25
Q1 25
-0.05×
Q4 24
13.55×
Q3 24
Q2 24
-5.09×
Q1 24
2.07×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons